（文章来源：证券日报） 证券日报网讯 2月25日，广济药业在互动平台回答投资者提问时表示，截至2026年2月13日，公司股东 总户数30602户。 ...

| 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 泸州老窖 | 000568 | 股权激励限售流通 | 204.25万 | | 中航西飞 | 000768 | 股权激励限售流通 | 436.06万 | | 湖北能源 | 000883 | 股权激励限售流通 | 1927.79万 | | 金陵药业 | 000919 | 股权激励限售流通 | 192万 | | 广济药业 | 000952 | 股权激励限售流通 | 252.09万 | | 中国软件 | 600536 | 股权激励限售流通 | 5.72万 | | 新华医疗 | 600587 | 股权激励限售流通 | 178.45万 | | 宝信软件 | 600845 | 股权激励限售流通 | 1025.78万 | | 中国中铁 | 601390 | 股权激励限售流通 | 5593.38万 | | 中国交建 | 601800 | 股权激励限售流通 | 559.3万 | | 星网锐捷 | 002396 | 股权激励限售流通 | 283.42万 | | 罗普斯金 | 002333 | 增发A股法人配售上市 ...

中国经济网北京2月22日讯 广济药业(000952.SZ)近日发布2026年向特定对象发行A股股票预案。公司本次发行拟 募集资金总额不超过60,000.00万元（含本数），扣除发行费用后用于偿还借款和补充流动资金。 本次向特定对象发行股票的发行对象为长江产业集团，拟以现金方式全额认购公司本次向特定对象发行的股 票。 本次向特定对象发行股票的定价基准日为第十一届董事会第十五次（临时）会议公告日。本次发行的发行价格 为6.32元/股，不低于定价基准日前二十个交易日公司股票交易均价的80%（定价基准日前二十个交易日股票交易均 价=定价基准日前二十个交易日股票交易总额/定价基准日前二十个交易日股票交易总量）。 本次发行股票数量不超过94,936,708股（含本数），不超过本次发行前公司总股本的30%，最终发行数量将在本 次发行通过深交所审核并经中国证监会同意注册后，按照相关规定，由上市公司股东会授权董事会根据中国证监会 相关规定及实际认购情况与保荐机构（主承销商）协商确定。 本次向特定对象发行的股票种类为人民币普通股（A股），每股面值为人民币1.00元。本次发行采取向特定对象 发行的方式。公司将在深交所审核通过并取得 ...

（文章来源：新京报） 新京报讯（记者刘旭）2月11日，湖北广济药业股份有限公司（简称"广济药业"）发布2026年向特定对 象发行A股股票预案，公司拟向控股股东长江产业集团发行股票募资不超过6亿元，扣除发行费用后将 全部用于偿还借款及补充流动资金。本次发行价格为6.32元/股。 广济药业表示，截至2025年9月30日，公司的资产负债率为62.67%，公司目前较高的资产负债率加大了 公司债务融资的成本，本次发行有利于公司优化资本结构，提高抗风险能力。同时，有利于稳固公司股 权结构，提升公司控制权稳定性；也有利于向社会公众传递积极信息，提升公司投资价值。 2025年10月以来，广济药业董事会曾四次审议通过向银行申请综合授信额度的议案，目的均为实现业务 发展和正常经营所需，包括：向中国民生银行股份有限公司武汉分行申请综合授信1.5亿元，授信期限1 年（其中中长期流动资金贷款支用额度不超过1亿元，期限不超过2年），担保方式为抵押，年利率不超 过3%；向华夏银行黄冈分行申请1.25亿元综合授信，其中1亿元可用于短期流动资金贷款，年利率不超 过2.98%，或开具1.25亿元银行承兑汇票，无抵押担保，资金用途包括采购原材料、 ...

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue up to 94,936,708 A-shares to its controlling shareholder, Changjiang Industrial Investment Group, raising a total of no more than 600 million yuan, which will improve the company's financial status and enhance its resilience against macroeconomic fluctuations [1][3] Group 1: Fundraising and Shareholding Structure - The fundraising will be used to repay loans and supplement working capital, which is expected to improve the company's financial condition [3][5] - After the issuance, Changjiang Industrial Group's shareholding will significantly increase, demonstrating the controlling shareholder's confidence in the company's long-term development [1][3] Group 2: Strategic Positioning and Industry Context - Changjiang Industrial Group is the only provincial-level industrial investment platform in Hubei, focusing on strategic emerging industries, including biomedicine [3][4] - The company aligns with Hubei's "14th Five-Year Plan," which emphasizes the development of high-end medical devices and biomedicine as key growth areas [4] Group 3: Business Structure and Competitive Advantages - Guangji Pharmaceutical is a major global supplier of Vitamin B2, with a market share of approximately 30%, and has a strong operational efficiency and cost control [5][7] - The company has a long history of technological accumulation in Vitamin B2 production, maintaining stable customer relationships and a robust supply chain [7][9] Group 4: Market Trends and Future Outlook - The Vitamin B2 market is entering a down cycle but is expected to recover as global feed demand increases and synthetic biology technology reshapes cost structures [9] - The 600 million yuan fundraising is seen as the beginning of a transformation from a traditional manufacturer to a health platform enterprise [9]

本报讯 （记者李万晨曦）2月12日，湖北广济药业股份有限公司（以下简称"广济药业"）公告拟向控股 股东长江产业投资集团有限公司（以下简称"长江产业集团"）定增募资。本次发行股票数量不超过 94936708股，价格为6.32元/股，募集资金总额不超过6亿元。 三是有利于向社会公众传递积极信息，提升本公司投资价值。本次发行的股票由公司控股股东全额认 购，向市场传递出积极信号，彰显控股股东长江产业集团对广济药业未来发展的坚定信心，有助于提振 二级市场投资情绪、树立公司正面形象，并进一步提高其投资价值，进而实现可持续发展、全体股东利 益最大化通过本次向特定对象发行股票，广济药业的财务状况将得到改善，募集资金使用方向为偿还借 款和补充流动资金，有利于加强其应对宏观经济波动的抗风险能力，从而提升公司的核心竞争能力和持 续盈利能力，实现股东利益最大化。 长江产业集团将现金全额认购，所购股份36个月内不得转让。资金主要用于偿还借款和补充流动资金， 以优化资本结构，降低资产负债率。据广济药业公告，此次定增的影响有以下几个方面： （编辑 张昕） 一是有利于广济药业优化资本结构，提高抗风险能力。截至2025年9月30日，该公司的资 ...

Core Viewpoint - Guangji Pharmaceutical (000952) plans to raise up to 600 million yuan through a private placement to its controlling shareholder, Changjiang Industrial Group, at a price of 6.32 yuan per share, aimed at optimizing its capital structure and addressing financial pressures [1] Group 1: Fundraising and Financial Strategy - The funds raised will be used to repay loans and supplement working capital, with the company's debt-to-asset ratio standing at 62.67% as of September 30, 2025 [1] - The controlling shareholder's stake will increase from 25.26% to 41.33%, indicating strong support for the company [1] Group 2: Performance Forecast - The company anticipates a net loss of between 399 million yuan and 518 million yuan for 2025, marking the third consecutive year of losses, following losses of 140 million yuan in 2023 and 295 million yuan in 2024 [1] - Revenue has declined for two consecutive years, with 2024 revenue reported at 639 million yuan, a year-on-year decrease of 13.42% [3] Group 3: Recent Developments - On February 13, 2026, the company announced the receipt of a drug registration certificate for Mecobalamin tablets, which are used for the treatment of peripheral neuropathy [1] - The company also faces potential shareholder compensation risks due to possible information disclosure issues [1] Group 4: Market Performance - Over the past week (February 9 to 13, 2026), Guangji Pharmaceutical's stock price has shown a slight upward trend, with a price increase of 1.64% and a trading range fluctuation of 5.29% [2] - On February 13, the stock closed at 8.07 yuan, up 1.51%, with a trading volume of 94.31 million yuan and a turnover rate of 3.35% [2] - Technical indicators suggest a weak bullish signal, with the stock touching the upper Bollinger Band at 8.33 yuan [2] Group 5: Institutional Insights - Overall institutional ratings are neutral, with no significant bullish or bearish views [4] - The fund holding ratio is only 0.04%, indicating low institutional interest and activity [4] - Market attention remains moderate, with no clear directional guidance from public sentiment regarding short-term events [4]

Policy Developments - The National Health Commission announced the initiation of HPV vaccination for eligible girls starting in late February, aiming to provide free vaccination services to prevent high-risk HPV infections and reduce cervical cancer incidence [2]. Drug and Device Approvals - Fosun Pharma's subsidiary received approval for clinical trials of HLX15-SC, a monoclonal antibody for multiple myeloma treatment, with a cumulative R&D investment of approximately RMB 191.53 million expected by January 2026 [4]. - Hanyu Pharmaceutical received FDA approval for its acetate glatiramer injection, which treats relapsing multiple sclerosis, enhancing its product pipeline in the U.S. market [5]. Capital Markets - Guangji Pharmaceutical plans to raise up to RMB 600 million through a private placement of shares to repay loans and supplement working capital, pending necessary approvals [7]. - Bonasia and Zhejiang Jingxin Pharmaceutical submitted applications for listing on the Hong Kong Stock Exchange, with respective sponsors [8][9]. Clinical Innovations - A successful brain-machine interface surgery was performed in Guangxi, marking a significant advancement in clinical applications of this technology, with the market projected to reach RMB 3.2 billion by 2024, growing at 18.8% [10]. Research Developments - Researchers from the Wuhan Institute of Virology reported that the oral nucleoside prodrug VV261 effectively inhibits Chikungunya virus replication, supporting its potential new indications [11]. - Northwestern University scientists developed an advanced human spinal cord injury organoid model, providing a platform for testing new regenerative therapies [12]. Public Sentiment Alerts - McAudie announced a lawsuit against Shenyang Sixth People's Hospital over a contract dispute involving over RMB 319.82 million, with the case currently accepted by the court [14]. - The National Medical Insurance Administration listed 153 companies as "discredited," which may face restrictions on their products and services based on their credit ratings [15].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 登录新浪财经APP 搜索【信披】查看更多考评等级 近日，湖北广济药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的甲钴胺片的《药品注册证书》。现将相关情况公告如下： 一、基本情况 1.药品通用名称：甲钴胺片 2.受理号：CYHS2402791 3.证书编号：2026S00402 4.剂型：片剂 5.包装规格：10片/板×2板/盒 6.注册分类：化学药品4类 7.药品注册标准编号：YBH01362026 8.上市许可持有人名称：湖北广济药业股份有限公司 地址：湖北省黄冈武穴市大金广济药业生物产业园A区 10.审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要 求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附执行。药品生产企业应 当符合药品生产质量管理规范要求方可生产销售。 11.药品批准文号：国药准字H20263341 二、药品的其他相关情况 甲钴胺片主要适用于周围神经病的治疗。 三、对公司的影响 本次甲钴胺片《药品注册证书》的获批，标志 ...

Group 1 - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue up to 94,936,708 A-shares to its controlling shareholder, Yangtze Industry Investment Group, raising a total of no more than 600 million RMB [1] - The purpose of the private placement is to repay company loans and supplement working capital, aiming to optimize capital structure and enhance financial stability [1] - As of September 2025, Guangji Pharmaceutical's debt-to-asset ratio is 62.67%, and the company has experienced continuous losses since 2023, with a projected net loss of between 399 million RMB and 518 million RMB for 2025 [1] Group 2 - The main reasons for the losses include long-term low prices in the vitamin B2 market and intense market competition, which have prevented sales prices from recovering [1] - The company believes that the private placement will enhance its risk resistance and reflects the controlling shareholder's confidence in the company's future development, which is beneficial for consolidating control [1] - The vitamin B2 market is expected to enter a phase of moderate growth starting in 2026 due to adjustments in market demand and opportunities for cost reduction from technological upgrades [1]